Trails.ai

Trials.ai provides a technology platform that utilizes artificial intelligence to enhance the design and efficiency of clinical trials. The company's Smart Protocol technology aims to accelerate the process of getting treatments to market by digitizing, automating, and adding intelligence to clinical trial design. The system analyzes vast amounts of data from past trials, medical journals, and regulatory documents to provide recommendations and insights, helping to optimize trials for speed, cost, risk, and patient-centricity. This approach transitions life science companies from a document-driven environment to a data-driven one, addressing the issue of making critical decisions with incomplete information.

The company was co-founded by Kim Walpole (CEO) and Tom Walpole (CTO). The inspiration for the company came from Kim Walpole's personal experience when her best friend was diagnosed with terminal pancreatic cancer. Frustrated by the slow pace of getting promising treatments "trial ready," she was motivated to find a way to accelerate clinical trials. This led to the formation of a team of experts in AI, business, and life sciences to develop the Trials.ai platform. The company has participated in several incubators and accelerators, including Evonexus, Nex Cubed, Dreamit, Nvidia Inception, and JLabs. Trials.ai was acquired by ZS Associates, allowing for an expansion of their team.

The platform serves life science companies and pharmaceutical firms by providing a decision support ecosystem. It operates by mining trial-related documents from both public and proprietary sources, using this data to power machine learning insights. The core business involves offering its web-based technology to clients to help them create optimized trial protocols, thereby reducing timelines and improving outcomes.

Keywords: clinical trial optimization, artificial intelligence, life sciences, protocol design, drug development, smart protocol, data mining, machine learning, patient centricity, regulatory technology, pharmaceutical services, trial efficiency, clinical research, healthtech, trial data analysis, decision support system, ZS Associates, Kim Walpole, Tom Walpole, David Fogel